Calmodulin kinase II inhibition protects against structural heart disease

By Rong-huai Zhang, M. Khoo, Yuejin Wu, Ying-bo Yang, Chad E. Grueter, G. Ni, E. Price, William H. Thiel, S. Guatimosim, Long‐Sheng Song and 9 more. Nature Medicine, 2005

619 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/aae7009d0ca87d0036246b8e0232ed7a1b552d67

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. I. Tabas
2. J. Heineke
3. J. Molkentin
4. G. Hotamışlıgil

In Molecular Biology

1. J. Heineke
2. D. Ron
3. D. Spitz
4. I. Tabas
5. J. Molkentin
6. R. Kaufman
7. J. Malhotra
8. G. Hotamışlıgil

Citations in the corpus

• Regulation of cardiac hypertrophy by intracellular signalling pathways (2006, background): “The genetic inhibition of CaMKII reduced hypertrophy and improved cardiac function during infusion of isoproterenol, which indicated that CaMK is necessary and sufficient for the induction of cardiac hypertroph”
• A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. (2008, methodology): “, 2007) and AC3-I mice (Zhang et al., 2005) are protected from left ventricular dilation and dysfunction after myocardial infarction surgery, suggesting that ROS activation of CaMKII may be important in myocardial infarction.”
• Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress (2011, background): “, and genetic or pharmacologic CaMKII inhibition blocks ER-stress-induced apoptosis in a number of disease model”